Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30483% above fair value
$4.06−0.25 (-5.80%)
Close on Nov 12, 2026Market cap $337.78MP/E –Yield –
Opus Genetics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Opus Genetics's enterprise value was $267.40M on Nov 11, 2026, against $107.73M a year earlier. Over the last 5 years it ranged from -$12.51M to $313.20M, with a median of $30.30M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $267.40M | +167.4% |
| 2025 | Dec 31, 2025 | $99.99M | – |
| 2024 | Dec 31, 2024 | -$5.46M | -121.2% |
| 2023 | Dec 29, 2023 | $25.70M | -56.8% |
| 2022 | Dec 30, 2022 | $59.47M | +42.0% |
| 2021 | Dec 31, 2021 | $41.88M | +99.5% |
| 2020 | Dec 31, 2020 | $21.00M | +24.9% |
| 2019 | Dec 31, 2019 | $16.81M | -84.1% |
| 2018 | Dec 31, 2018 | $105.52M | -52.4% |
| 2017 | Dec 29, 2017 | $221.73M | +78.0% |
| 2016 | Dec 30, 2016 | $124.53M | -49.7% |
| 2015 | Dec 31, 2015 | $247.83M | -48.8% |
| 2014 | Dec 31, 2014 | $484.14M | +86.6% |
| 2013 | Dec 31, 2013 | $259.39M | +134.0% |
| 2012 | Dec 31, 2012 | $110.85M | -15.8% |
| 2011 | Dec 30, 2011 | $131.59M | – |
See a number that looks wrong?